for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

アステラス製薬株式会社

4503.T

現在値

1,966.00JPY

変化

-1.50(-0.08%)

出来高

1,131,200

本日のレンジ

1,959.00

 - 

1,972.00

52週レンジ

1,426.00

 - 

2,025.00

∙ 約20分前の相場を表示しています。

適時開示

Seagen Says Japan’S MHLW Approves Padcev (Enfortumab Vedotin) For Advanced Urothelial Cancer

Sept 27 (Reuters) - :JAPAN’S MHLW APPROVES PADCEV® (ENFORTUMAB VEDOTIN) FOR ADVANCED UROTHELIAL CANCER.SEAGEN INC - APPROVAL IS PRIMARILY BASED ON GLOBAL PHASE 3 EV-301 CLINICAL TRIAL, WHICH INCLUDED SITES IN JAPAN.SEAGEN INC - NEW DRUG APPLICATION RECEIVED PRIORITY REVIEW.

Astellas Receives European Commission Approval For First-In-Class Evrenzo (Roxadustat) For Adult Patients With Symptomatic Anemia Of Chronic Kidney Disease

Aug 19 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS RECEIVES EUROPEAN COMMISSION APPROVAL FOR FIRST-IN-CLASS EVRENZO (ROXADUSTAT) FOR ADULT PATIENTS WITH SYMPTOMATIC ANEMIA OF CHRONIC KIDNEY DISEASE.EC APPROVAL OF ROXADUSTAT TRIGGERS A MILESTONE PAYMENT OF $120 MILLION BY CO TO FIBROGEN.FIBROGEN WILL ALSO RECEIVE ROYALTIES BASED UPON EUROPEAN NET SALES.

U.S. FDA Grants Regular Approval And Expands Indication For PADCEV (Enfortumab Vedotin-Ejfv) For Patients With Locally Advanced Or Metastatic Urothelial Cancer

July 9 (Reuters) - U.S. FDA ::U.S. FDA GRANTS REGULAR APPROVAL AND EXPANDS INDICATION FOR PADCEV® (ENFORTUMAB VEDOTIN-EJFV) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.

Astellas Will Book An Impairment Loss Of 21.5 Billion Yen After Terminating Development Of Dna Vaccine For Peanut Allergy

June 17 (Reuters) - :ASTELLAS WILL BOOK AN IMPAIRMENT LOSS OF 21.5 BILLION YEN AFTER TERMINATING DEVELOPMENT OF DNA VACCINE FOR PEANUT ALLERGY.

Astellas Pharma Inc - Will Offer Early Retirement Incentive Program

June 3 (Reuters) - Astellas Pharma Inc <4503.T>::WILL OFFER EARLY RETIREMENT INCENTIVE PROGRAM.ESTIMATED NUMBER OF APPLICANTS IS ABOUT 450.IMPACT ON FINANCIAL RESULTS TO BE ANNOUNCED ONCE FINALISED.

Seagen And Astellas Announce Updated Results From Two Trials Of Padcev In Patients With Locally Advanced Or Metastatic Urothelial Cancer Not Eligible For Cisplatin Chemotherapy

May 19 (Reuters) - Astellas Pharma Inc <4503.T>::SEAGEN AND ASTELLAS ANNOUNCE UPDATED RESULTS FROM TWO TRIALS OF PADCEV® (ENFORTUMAB VEDOTIN-EJFV) IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER NOT ELIGIBLE FOR CISPLATIN CHEMOTHERAPY.SEAGEN - DURABLE RESPONSES OBSERVED IN SECOND COHORT OF PATIENTS IN PIVOTAL EV-201 TRIAL OF PADCEV, IN INITIAL FIRST-LINE COHORT OF EV-103 TRIAL.SEAGEN INC - FOUR DEATHS WERE PREVIOUSLY REPORTED AS TREATMENT-RELATED BY INVESTIGATORS IN PATIENTS AGE 75 YEARS AND OLDER WITH MULTIPLE COMORBIDITIES.

Astellas, Seagen Report U.S. FDA Acceptance Of Two Supplemental Biologics License Applications For PADCEV

April 19 (Reuters) - Seagen Inc <SGEN.O>::ASTELLAS AND SEAGEN ANNOUNCE U.S. FDA ACCEPTANCE OF TWO SUPPLEMENTAL BIOLOGICS LICENSE APPLICATIONS FOR PADCEV® (ENFORTUMAB VEDOTIN-EJFV) IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.SEAGEN INC - PRIORITY REVIEW FOR PADCEV GRANTED WITH ACTION DATE OF AUGUST 17.SEAGEN INC - AUSTRALIA AND CANADA REGULATORS WILL REVIEW PADCEV APPLICATIONS AS PART OF FDA'S PROJECT ORBIS.

Seagen, Astellas Report U.S. FDA Acceptance Of Two Supplemental Biologics License Applications For PADCEV

April 19 (Reuters) - Seagen Inc <SGEN.O>::SEAGEN AND ASTELLAS ANNOUNCE U.S. FDA ACCEPTANCE OF TWO SUPPLEMENTAL BIOLOGICS LICENSE APPLICATIONS FOR PADCEV® (ENFORTUMAB VEDOTIN-EJFV) IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.SEAGEN INC - APPLICATIONS WERE GRANTED PRIORITY REVIEW, WITH A TARGET ACTION DATE OF AUGUST 17, 2021.

FDA Approves New Indication For Drug To Treat Neurogenic Detrusor Overactivity In Pediatric Patients

March 25 (Reuters) - Astellas Pharma Inc <4503.T>::FDA APPROVES NEW INDICATION FOR DRUG TO TREAT NEUROGENIC DETRUSOR OVERACTIVITY IN PEDIATRIC PATIENTS.FDA - GRANTED APPROVAL OF MYRBETRIQ AND MYRBETRIQ GRANULES TO ASTELLAS PHARMA US, INC.

Astellas And Seagen Announce Submission Of Two Supplemental Biologics License Applications To The U.S. FDA For Padcev In Locally Advanced Or Metastatic Urothelial Cancer

Feb 18 (Reuters) - Seagen Inc <SGEN.O>::ASTELLAS AND SEAGEN ANNOUNCE SUBMISSION OF TWO SUPPLEMENTAL BIOLOGICS LICENSE APPLICATIONS TO THE U.S. FDA FOR PADCEV® (ENFORTUMAB VEDOTIN-EJFV) IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.SEAGEN INC - SUBMISSIONS WILL BE REVIEWED UNDER REAL-TIME ONCOLOGY REVIEW BASED ON CLINICAL TRIALS EV-301 AND COHORT 2 OF EV-201.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up